{
    "organizations": [],
    "uuid": "8105c14ace95197fbe723b02b78a8a04b18602cc",
    "author": "",
    "url": "https://www.reuters.com/article/brief-vaxil-obtains-us-patent-for-signal/brief-vaxil-obtains-u-s-patent-for-signal-peptide-antibody-platform-idUSFWN1QJ0U9",
    "ord_in_thread": 0,
    "title": "BRIEF-Vaxil‍ Obtains U.S. Patent For Signal Peptide Antibody Platform",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1, 2018 / 1:47 PM / in 12 minutes BRIEF-Vaxil‍ Obtains U.S. Patent For Signal Peptide Antibody Platform Reuters Staff 1 Min Read March 1 (Reuters) - Vaxil Bio Ltd: * VAXIL BIO LTD - ‍ OBTAINED A U.S. PATENT FOR ITS SIGNAL PEPTIDE ANTIBODY PLATFORM KNOWN AS SPMAB​ * VAXIL BIO LTD - ‍ SAEID BABAEI HAS RESIGNED FROM HIS ROLE AS CHAIRMAN OF BOARD​ * VAXIL BIO LTD - ‍ISAAC MARESKY HAS ACCEPTED ROLE OF CHAIRMAN FOR TIME BEING​ Source text for Eikon:  ",
    "published": "2018-03-01T15:45:00.000+02:00",
    "crawled": "2018-03-01T16:01:18.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "minute",
        "obtains",
        "patent",
        "signal",
        "peptide",
        "antibody",
        "platform",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "vaxil",
        "bio",
        "ltd",
        "vaxil",
        "bio",
        "ltd",
        "obtained",
        "patent",
        "signal",
        "peptide",
        "antibody",
        "platform",
        "known",
        "vaxil",
        "bio",
        "ltd",
        "saeid",
        "babaei",
        "resigned",
        "role",
        "chairman",
        "vaxil",
        "bio",
        "ltd",
        "maresky",
        "accepted",
        "role",
        "chairman",
        "time",
        "source",
        "text",
        "eikon"
    ]
}